

**Disclosure Purpose:** 21-07659

## Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
<a href="#">Novavax, Inc.</a>	Employment	Self
<i>Title:</i> Senior Director, Medical Writing		<i>Position Description:</i> Responsible for writing clinical documentation in support of regulatory approval of Company investigational products.
<i>Additional Information:</i>		

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-07659

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- 3. **Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-07659

Summary of Interests

**Company or Organization**

Entity	Type	Interest Held By
<a href="#">GlaxoSmithKline</a>	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> COVID monoclonal antibody advisory board and speaker
<a href="#">Roche</a>	Grant / Contract	Self
<i>Recipient Name:</i> Chelsea and Westminster Hospital <i>Grant / Contract Description:</i> Phase II study grant <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
<a href="#">Valneva Austria GmbH</a>	Grant / Contract	Self
<i>Recipient Name:</i> Chelsea and Westminster Hospital <i>Grant / Contract Description:</i> Phase III study grant <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-07659

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Efficacy of the NVX-CoV2373 Covid-19 Vaccine 302
- 3. **Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-07659

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- 3. **Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-07659

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-07659

Summary of Interests

**Company or Organization**

Entity	Type	Interest Held By
NVAX	Employment	Self
<i>Title:</i> Vice President, Biostatistics <i>Additional Information:</i>		<i>Position Description:</i> Head of Biostatistics Group
NVAX	Stock Option	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-07659

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.





**Disclosure Purpose:** 21-07659

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- 3. **Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-07659

## Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Novavax	Employment	Self
<i>Title:</i> Chief Medical Officer <i>Additional Information:</i> I am a full-time employee and own stock in Novavax		<i>Position Description:</i> Executive Vice-President

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-07659

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-07659

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
AbbVie	Consultant	Self
Category: Consultant Additional Information:		Description: Speaker fees
Chugai Pharmaceutical	Consultant	Self
Category: Consultant Additional Information:		Description: Speaker fees
Eli Lilly and Company	Consultant	Self
Category: Consultant Additional Information:		Description: Speaker fees, advisory board
Gilead Sciences	Consultant	Self
Category: Consultant Additional Information:		Description: Speaker fees and advisory board
Janssen Biotech	Consultant	Self
Category: Consultant Additional Information:		Description: Speaker fees and advisory board
Novartis	Consultant	Self
Category: Consultant Additional Information:		Description: Speaker fees
Pfizer	Consultant	Self
Category: Consultant Additional Information:		Description: Speaker fees and advisory board
Sobi, Inc	Consultant	Self
Category: Consultant Additional Information:		Description: Speaker fees

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  
No.
- What is the manuscript title?  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant
- Are you the corresponding author?  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-07659

Summary of Interests

**Company or Organization**

Entity	Type	Interest Held By
Novavax, Inc	Employment	Self
<i>Title:</i> President, Research & Development <i>Additional Information:</i>		<i>Position Description:</i>
Novavax, Inc	Stock	Self
<i>Additional Information:</i> Stakeholder		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-07659

Summary of Interests

**Company or Organization**

Entity	Type	Interest Held By
Novavax	Grant / Contract	Other - Institution
<i>Recipient Name:</i> Guys and St Thomas NHS Foundation trust		<i>Recipient Type:</i> Institution
<i>Grant / Contract Description:</i> Contract to deliver the vaccine trial		<i>Grant / Contract Purpose:</i> Research
<i>Additional Information:</i>		

**Intellectual Property**

Type	Is Licensed	Interest Held By
Patent - Long Promoter Patent	No	Self
<i>Description:</i> Long Promoter Patent <i>Patent Status:</i> Issued <i>Filing Jurisdiction:</i> GBR <i>Licensees:</i>		<i>Patent Number:</i> OUI3266 <i>Patent Holder:</i> Previous Institution
<i>Additional Information:</i> This is a patent relating to the ChAdOx1 Astra Zeneca vaccine. Oxford University have entered into a partnership with Astra Zeneca and as a named inventor on a patent covering use of a particular promoter technology this may be perceived as a conflict. This technology is not used in the novavax vaccine construct.		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-07659

## Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
<a href="#">Novavax</a>	Grant / Contract	Other - Institution
<i>Recipient Name:</i> St Georges University of London <i>Grant / Contract Description:</i> research grant <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-07659

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- 3. **Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.





**Disclosure Purpose:** 21-07659

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-07659

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant
- 3. **Are you the corresponding author?**  
Yes.
  - a. **Please list the other authors' names here.**  
Dr.Toback

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-07659

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-07659

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-07659

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-07659

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-07659

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
<a href="#">Bayer</a>	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Intermittent consultancy. £250 per hour		<i>Description:</i> Consultancy for treatment of ARDS
<a href="#">Boehringer Ingelheim</a>	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Intermittent consultancy. £250 per hour		<i>Description:</i> Consultancy for treatment of ARDS and COVID-19
<a href="#">Eli Lilly &amp; Co Ltd</a>	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Intermittent consultancy. £220 per hour		<i>Description:</i> Consultancy for treatment of COVID-19
<a href="#">GlaxoSmithKline</a>	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Intermittent consultancy. Currently up to £360 per hour		<i>Description:</i> Consultancy for treatments of ARDS and COVID-19 and educational seminar speaker for COVID-19
<a href="#">Novartis Pharma</a>	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> £318 per hour		<i>Description:</i> Consultancy for treatment of COVID-19
<a href="#">Novavax</a>	Grant / Contract	Self
<i>Recipient Name:</i> Prof Danny McAuley <i>Grant / Contract Description:</i> Grant for conduct of study <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
<a href="#">Vir Biotechnology Inc</a>	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> £300 per hour		<i>Description:</i> Member DMEC for COVID-19 trial

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.
- What is the manuscript title?**

Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- Are you the corresponding author?**

No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-07659

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Vaccine
- 3. **Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.





**Disclosure Purpose:** 21-07659

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- 3. **Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-07659

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-07659

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-07659

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-07659

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- 3. Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-07659

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-07659

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-07659

Summary of Interests

**Company or Organization**

Entity	Type	Interest Held By
Novavax, Inc	Employment	Self
<i>Title:</i> Clinical Research Scientist		<i>Position Description:</i>
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-07659

## Summary of Interests

I do not have any interests to disclose at this time.

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-07659

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-07659

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-07659

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Title: Effects of screening and selective fall prevention interventions for reducing fractures.
- 3. **Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-07659

## Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
<a href="#">Novavax Inc</a>	Employment	Self
<i>Title:</i> Executive Director, Global Safety Medical Lead <i>Additional Information:</i>		<i>Position Description:</i>

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-07659

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- 3. **Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-07659

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- 3. Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-07659

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Safety and efficacy of the NVX-CoV2373 Covid-19 Vaccine
- 3. **Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.





**Disclosure Purpose:** 21-07659

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-07659

Summary of Interests

**Company or Organization**

Entity	Type	Interest Held By
Novavax	Employment	Self
<i>Title:</i> Vice President Clinical Development <i>Additional Information:</i> Salaried employee		<i>Position Description:</i> full time employee
Novavax	Stock	Self
<i>Additional Information:</i> Stock is a component of my compensation		

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Safety and Efficacy of NVXCoV2373 Covid-19 Vaccine

3. Are you the corresponding author?

Yes.

a. Please list the other authors' names here.

Paul T. Heath<sup>1</sup>, FRCPC, Eva P. Galiza<sup>1</sup>, MBBS, David Neil Baxter<sup>2</sup>, MD, PhD, Marta Boffito<sup>3</sup>, MD, PhD, Duncan Browne<sup>4</sup>, MD, Fiona Burns<sup>5</sup>, PhD, David R. Chadwick<sup>6</sup>, PhD, Rebecca Clark<sup>7</sup>, MBChB, Catherine Cosgrove<sup>1</sup>, PhD, James Galloway<sup>8</sup>, PhD, Anna L. Goodman<sup>9</sup>, DPhil, Amardeep Heer<sup>10</sup>, MBChB, Andrew Higham<sup>11</sup>, PhD, Shalini Iyengar<sup>12</sup>, MBBS, Arham Jamal<sup>13</sup>, MBBCh, Christopher Jeanes<sup>14</sup>, MBBS, Philip A. Kalra<sup>15</sup>, MD, Christina Kyriakidou<sup>16</sup>, MD, Daniel F. McAuley<sup>17</sup>, MD, Agnieszka Meyrick<sup>18</sup>, MD, Angela M. Minassian<sup>19</sup>, DPhil, Jane Minton<sup>20</sup>, PhD, Patrick Moore<sup>21</sup>, BScBM, Imrozia Munsoor<sup>22</sup>, MBBS, Helen Nicholls<sup>23</sup>, MBBCh, Orod Osanlou<sup>24</sup>, MBChB, Jonathan Packham<sup>25</sup>, DM, Carol H. Pretswell<sup>26</sup>, MBChB, Alberto San Francisco Ramos<sup>1</sup>, MB, Dinesh Saralaya<sup>27</sup>, MD, Ray P. Sheridan<sup>28</sup>, MBChB, Richard Smith<sup>29</sup>, PhD, Roy L. Soiza<sup>30</sup>, MBChB, Pauline A. Swift<sup>31</sup>, PhD, Emma C. Thomson<sup>32</sup>, PhD, Jeremy Turner<sup>14</sup>, DPhil (Oxon), Marianne Elizabeth Vijoen<sup>33</sup>, MBChB, Gary Albert<sup>34</sup>, MS, Iksung Cho<sup>34</sup>, MS, Filip Dubovsky<sup>34</sup>, MD, Greg Glenn<sup>34</sup>, MD, Joy Rivers<sup>34</sup>, PhD, Andrea Robertson<sup>34</sup>, MS, Kathy Smith<sup>34</sup>, MD

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-07659

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-07659

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Safety and efficacy in the NVXCoV-2373 COVID-19 vaccine
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.